Novo Nordisk’s Pill Sales Beat Buys Time as Pricing Squeeze Intensifies
Oral Wegovy pill drives Q1 beat with sales doubling forecasts, but Maryland price cap, Supreme Court ruling, and…
Q1 Earnings Loom as Valuation Debate Intensifies
Novo Nordisk faces pivotal Q1 earnings amid a 36% YTD stock drop, competitive pressure from Eli Lilly, and…
Novo Nordisk’s Pill Price War Intensifies as AI Strategy Unfolds
Novo Nordisk slashes prices and partners with OpenAI as its oral weight-loss drug faces fierce competition from Eli…
Novo Nordisk Faces Mounting Challenges as Competition Intensifies
Novo Nordisk cuts 2026 sales outlook amid generic competition in India, U.S. price pressures, and Eli Lilly’s new…
Regulatory Scrutiny Intensifies for Novo Nordisk Over Drug Safety Reporting
Regulatory, Scrutiny
15.03.2026 – 03:44:25 | boerse-global.de
FDA mandates corrective action after inspection finds…
Regulatory Spotlight Intensifies on Novo Nordisk’s GLP-1 Portfolio
FDA cracks down on compounded semaglutide claims and Novo Nordisk’s Ozempic ad, while the firm invests €432M in…
Regulatory Spotlight Intensifies on Novo Nordisk’s Marketing and Market
FDA warns 30 firms over compounded semaglutide claims and reprimands Novo Nordisk for Ozempic ad. The dual action…
Novo Nordisk Shifts Strategy as US Weight-Loss Drug Price War Intensifies
The battle for dominance in the lucrative US market for weight-loss medications is entering a new phase. In…